Endocrine Today Current Issue
The following articles appeared in the print edition of Endocrine Today.
Table of Contents
- Artificial pancreas: closer to an optimal treatment for diabetes?
-
- Physicians must educate patients about obesity
- Television marketing plays large role in youth obesity
- Valproate, antipsychotic drugs and HAART have additional endocrine disruptor effects Alan Sacerdote, MD, FACP
- What’s in a name? Stephen Brieztke, MD
- FDA panel recommends approval for OTC orlistat 60 mg
- FDA approves inhaled insulin for diabetes
- IV treatment for postmenopausal osteoporosis approved
- Aldosteronism increases risk for metabolic syndrome, adverse events
-
- Calcium plus vitamin D offered only modest improvement of bone mineral density
- Corticotropin test reliable for excluding secondary adrenal insufficiency
- Even brief diabetes education programs aid self-management
- Growth hormone therapy for Prader-Willi syndrome can worsen sleep problems
- High insulin levels and insulin resistance may predict risk of pancreatic cancer
- IV insulin control adapted to intermediate-care units
- Low-fat diets did not reduce risk of colorectal or breast cancer, CVD in postmenopausal women
- Periodontal disease can begin early in diabetes
-
- Rimonabant found beneficial for CVD risk reduction
- Safety profile of gatifloxacin questioned; labeling changes made
- Scaffolds, antibiotics and wound pressure show promise in treating diabetic foot sores
- Thyroid hormone withdrawal in differentiated thyroid carcinoma: substantial societal costs?
- Variant gene an intriguing find for diabetes research
- Work-hour restrictions affect emotional health, job satisfaction, education
- FIELD: Mixed results found with fenofibrate therapy among patients with diabetes